



HHS Public Access

Author manuscript

Sci Immunol. Author manuscript; available in PMC 2022 April 22.

Published in final edited form as:

Sci Immunol. 2021 October 22; 6(64): eabj3859. doi:10.1126/sciimmunol.abj3859.

NLRP3 inflammasome activation triggers gasdermin D-independent inflammation

Chun Wang^{1,\$}, Tong Yang^{1,2,\$}, Jianqiu Xiao^{1,\$}, Canxin Xu³, Yael Alippe¹, Kai Sun^{1,2}, Thirumala-Devi Kanneganti⁴, Joseph B. Monahan³, Yousef Abu-Amer^{5,6}, Judy Lieberman⁷, Gabriel Mbalaviele^{1,*}

¹Division of Bone and Mineral Diseases, Washington University School of Medicine, St. Louis, MO 63110, USA

²Department of Spine Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China

³Aclaris Therapeutics, Inc., St. Louis, MO 63108, USA

⁴Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA

⁵Department of Orthopaedic Surgery, Washington University School of Medicine, St. Louis, Missouri, USA

⁶Shriners Hospital for Children, St. Louis, Missouri, USA

⁷Program in Cellular and Molecular Medicine, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA 02115 USA

Abstract

NOD-like receptor (NLR), family pyrin domain containing 3 (NLRP3) assembles an intracellular protein complex known as the NLRP3 inflammasome upon sensing certain pathogen products or sterile danger signals. Gain-of-function mutations such as the D301N substitution in NLRP3, which cause its constitutive activation (NLRP3^{CA}) also results in inflammasome assembly. This inflammasome processes pro-interleukin-1 β (pro-IL-1 β) and pro-IL-18 into bioactive IL-1 β and IL-18, respectively, and cleaves gasdermin D (GSDMD). GSDMD N-terminal fragments form plasma membrane pores that facilitate the secretion of IL-1 β and IL-18 and lead to the inflammatory cell death pyroptosis. Accordingly, GSDMD inactivation results in negligible spontaneous inflammation in various experimental models such as in *Nlrp3*^{CA/+} mice lacking GSDMD (*Nlrp3*^{CA/+}; *Gsdmd*^{-/-} mice). Here, we found that *Nlrp3*^{CA/+}; *Gsdmd*^{-/-} mice, when challenged with LPS or TNF- α , still secreted IL-1 β and IL-18, indicating inflammasome

*To whom correspondence should be addressed. Division of Bone and Mineral Diseases, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8301, St. Louis, MO 63110, Phone: (314) 286-1114; Fax: (314) 454-5047; gmbalaviele@wustl.edu.

^{\$}These authors contributed equally to this work

Author contributions: Conceptualization: CW, GM; Methodology: CW, TY, JQ, CX, YA, KS, GM; Writing – original draft: CW, GM; Writing – review & editing: CW, TDK, JBM, YA, JL, GM.

Competing interest: GM is Consultant for Aclaris Therapeutics, Inc. CX and JBM are employees of Aclaris Therapeutics, Inc. They have no additional financial interests. JL is cofounder and SAB member of Ventus Therapeutics and has filed a patent application for the use of disulfiram for inhibiting pyroptosis and inflammation. All other authors declare no competing financial interests.

Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper of supplementary materials.

activation independent of GSDMD. Accordingly, *Gsdmd*^{-/-} macrophages failed to secrete IL-1 β and undergo pyroptosis when briefly exposed to NLRP3 inflammasome activators (LPS and nigericin), but released these cytokines when persistently activated. Sustained NLRP3 inflammasome induced caspase-8/-3 and GSDME cleavage, and IL-1 β maturation *in vitro* in *Gsdmd*^{-/-} macrophages. Thus, a salvage inflammatory pathway involving caspase-8/-3-GSDME was activated following NLRP3 activation when the canonical NLRP3-GSDMD signaling was blocked. Consistent with genetic data, the active metabolite of FDA-approved disulfiram CuET, which inhibited GSDMD and GSDME cleavage in macrophages, reduced the severe inflammation and tissue damage that occurred in the *Nlrp3*^{CA} mice. Thus, NLRP3 inflammasome activation overwhelms the protection afforded by GSDMD deficiency, rewiring signaling cascades through mechanisms that include GSDME to propagate inflammation.

ONE SENTENCE SUMMARY

Sustained stimulation of the NLRP3 inflammasome causes inflammation in the absence of GSDMD.

INTRODUCTION

The innate immune receptor NOD-like receptor (NLR), family pyrin domain containing 3 (NLRP3) assembles an intracellular protein complex known as the NLRP3 inflammasome upon sensing plasma membrane perturbations caused by certain microbial products or sterile danger signals (1-3). This inflammasome leads to cell death and inflammatory responses. The macromolecular structure of the inflammasome is formed by NLRP3, the adaptor protein apoptosis-associated speck-like protein containing a CARD (ASC), and caspase-1, which becomes activated when it is recruited to inflammasomes. Caspase-1, which is activated by all the canonical inflammasomes, cleaves inactive pro-interleukin-1 β (pro-IL-1 β) and pro-IL-18 into bioactive IL-1 β and IL-18, respectively (2, 3); it also cleaves gasdermin D (GSDMD), generating N-terminal fragments which oligomerize within the plasma membrane to form pores through which IL-1 β and IL-18 are secreted (4-8). Excessive pore formation compromises the integrity of the plasma membrane, causing a lytic form of cell death known as pyroptosis. In some situations, cells can survive GSDMD activation but still release inflammatory cytokines in a GSDMD-dependent process, thus have been termed “hyperactivated” (6). Pyroptosis is a double-edged sword - it releases inflammatory factors that recruit immune cells to sites of pathogenic infection, which attack and phagocytose pathogens, destroy their replication niches and boost adaptive immune responses (9, 10). However, excessive or uncontrolled pyroptosis and inflammatory cytokine release can lead to organ damage, circulatory collapse or even death (11-13).

GSDMD is also cleaved by caspase-11 (mouse ortholog of human caspase-4 and -5) (14), neutrophil elastase and cathepsin G (15-18), caspase-3 (19), and caspase-8 (20, 21). Cleavage by all of these proteases, except caspase-3 which inactivates GSDMD, produces a pore-forming N-terminal fragment. Caspase-3 also cleaves gasdermin E (GSDME, also known as DNFA5), producing active N-terminal fragments whose pore-forming activity promotes pyroptosis in response to apoptotic stimuli (22-24), including chemotherapeutic drugs (25, 26), *Yersinia* infection (20), glucocorticoid treatment (24), and inflammasome

activators in cells lacking GSDMD or caspase-1 (27, 28). GSDME is also a substrate of granzyme B (23, 29). The role of GSDME in cell death may be cell context-dependent as it is seemingly dispensable for pyroptosis in certain cell types or experimental conditions (19, 20, 30-33). The function of GSDME in mediating the release of inflammatory cytokines is less studied. A recent study reported that IL-1 α was secreted through GSDME conduits in *caspase-1* and *-11* deficient macrophages, but pro-IL-1 β was neither processed nor released (28). Thus, like GSDMD, cleaved GSDME generates pore-forming fragments that can release cytokines and cause pyroptosis.

Chronic activation of the NLRP3 inflammasome by endogenous host danger-associated molecular patterns and the ensuing excessive production of IL-1 β and IL-18 underlie the pathogenesis of several autoimmune and autoinflammatory diseases, including inflammatory bowel disease (34-36) and rheumatoid arthritis (37-39), and contribute to the severity of atherosclerosis (40, 41), gout (42-45), and diabetes (46). Gain-of-function mutations in *NLRP3* cause a spectrum of autoinflammatory disorders known as cryopyrin-associated periodic syndromes (CAPS), whose severity is linked to specific *NLRP3* mutations. Neonatal-onset multisystem inflammatory disease (NOMID) is the most severe and familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS) are less severe (12, 13). Clinical manifestations of CAPS include systemic inflammation, skin lesions, central nervous system symptoms including headache, hearing loss and learning difficulties, and skeletal anomalies (13, 47-51). Mice genetically engineered to express NLRP3 variants that harbor mutations found in CAPS patients (NLRP3^{CA}) develop severe systemic inflammation characterized by excessive secretion of IL-1 β and IL-18, multi-organ damage, and premature death (52, 53). Although young NOMID mice lacking the IL-1 receptor do not develop inflammation (54), a persistent low-grade inflammation is reported in FCAS mice and MWS mice with defective IL-1 and IL-18 signaling (55), suggesting that pyroptosis may be the culprit. In support of this view, knocking out GSDMD prevents the pathogenesis of NOMID (56), Familial Mediterranean Fever (FMF) (57), and experimental autoimmune encephalitis (58). However, how these mutant mice with an underlying dysregulated NLRP3 inflammasome activity withstand superimposed inflammatory challenges has not been studied.

CAPS and several other diseases of dysregulated inflammasome activity, including FMF and macrophage activation syndrome which are caused by *PYRIN* and *NLR4* mutations, respectively, are treated with IL-1 blockers (59). These therapies have significantly improved the quality of life of affected individuals, but the disease does not always resolve (60-63). The underlying mechanisms of resistance are not understood, but lingering low-grade inflammation driven by IL-18 and pyroptosis is suspected. To identify drugs that block the integrating nodes of inflammasome signaling, recent studies screened several safe marketed drugs for anti-GSDMD activity. They identified disulfiram, also known as Antabuse, an FDA-approved drug for the treatment of alcohol addiction, and dimethyl fumarate, also known as Tecfidera used to treat multiple sclerosis, as inhibitors of GSDMD and pyroptosis (58, 64). Both drugs also inhibited LPS-induced IL-1 β and IL-18 secretion *in vitro* and *in vivo* (65). These observations provide a rationale for evaluating pyroptosis inhibitors in animal inflammasomopathy models.

In this study, we used mice bearing one allele of *Nlrp3* with D301N substitution, which induces constitutive activation of NLRP3 (NLRP3^{CA}), and challenged them with inflammatory stimuli (LPS or TNF- α) to understand better the role of GSDMD in promoting inflammation. We found that NLRP3 inflammasome activation caused IL-1 family cytokine secretion and pyroptosis in *Gsdmd*^{-/-} cells, responses that were associated with caspase-8/-3 and GSDME cleavage. The active metabolite of disulfiram, bis(diethyldithiocarbamate)-copper (CuET), inhibited the cleavage of both GSDMD and GSDME as well as ASC activation, protecting mice from the pathology caused by dysregulated NLRP3 inflammasome. Thus, the inflammatory actions of dysregulated NLRP3 inflammasome involve GSDME in *Gsdmd*^{-/-} cells and are inhibited by CuET.

RESULTS

***Gsdmd* deficient mice expressing hyperactive NLRP3 inflammasome aged normally**

D301N substitution in NLRP3 imposes conformational changes and constitutive activation of NLRP3 (NLRP3^{CA}); this autosomal dominant mutation ultimately causes an inflammatory disease in *Nlrp3*^{CA/+} mice that resembles human NOMID (52, 66). Most *Nlrp3*^{CA/+} mice die prematurely around 3 weeks of age due to severe systemic inflammation that damages multiple organs, including the skin, brain, bones, and spleen (52, 66, 67). *Gsdmd*^{-/-} and *Nlrp3*^{CA/+} mice lacking GSDMD (*Nlrp3*^{CA/+};*Gsdmd*^{-/-} mice) grow normally and are indistinguishable from their wild-type (WT) counterparts when monitored for up to 66 days, indicating strong GSDMD-dependence of inflammation in NOMID mice (56). However, mice expressing constitutively activated NLRP3 as a result of L351P substitution that are genetically deficient in *Il-1* and *Il-18* unexpectedly show signs of lingering inflammation (55). This finding prompted us to monitor *Nlrp3*^{CA/+};*Gsdmd*^{-/-} mice for longer time periods. Mouse survival, white blood cell (WBC) counts, and spleen weight of *Nlrp3*^{CA/+};*Gsdmd*^{-/-} and *Gsdmd*^{-/-} mice remained indistinguishable at 6 months and 12 months of age (fig. S1A). Accordingly, the architecture of the spleen and the liver was histologically similar between both genotypes (fig. S1, B and C). Thus, *Nlrp3*^{CA/+};*Gsdmd*^{-/-} mice age normally in homeostatic conditions, consistent with our previous study (56).

LPS or TNF- α induced IL-1 β and IL-18 secretion in *Nlrp3*^{CA/+};*Gsdmd*^{-/-} but not *Gsdmd*^{-/-} mice.—*Gsdmd*^{-/-} mice, unlike caspase-11^{-/-} mice, are not fully protected from death caused by a lethal dose of LPS (14), suggesting that there might be a GSDMD-independent inflammatory pathway. Baseline blood serum IL-1 β , IL-18, and IL-6 were low and comparable in WT and *Gsdmd*^{-/-} mice but were constitutively increased in *Nlrp3*^{CA/+} mice and returned to normal in *Nlrp3*^{CA/+};*Gsdmd*^{-/-} mice as expected (Fig. 1). After LPS challenge, serum IL-1 β and IL-18 increased in WT mice, but not in *Gsdmd*^{-/-} mice. However, in *Nlrp3*^{CA/+} mice these cytokine levels were about 10-fold higher than in LPS-stimulated WT mice and surprisingly were not substantially reduced in *Nlrp3*^{CA/+};*Gsdmd*^{-/-} mice. LPS stimulated high serum levels of IL-6 and CXCL1 in all the genotypes. TNF- α injection increased serum IL-1 β and IL-18 in *Nlrp3*^{CA/+}, but not in WT or *Gsdmd*^{-/-} mice, but this increase was significantly reduced but not eliminated in *Nlrp3*^{CA/+};*Gsdmd*^{-/-} mice. TNF- α also elevated serum IL-6 and CXCL1 in all genotypes, but induced more IL-6 in *Nlrp3*^{CA/+} mice which was still above the level in WT mice (Fig. 1). These results indicate

that both GSDMD-dependent and GSDMD-independent inflammation is induced in the setting of intense NLRP3 inflammasome activation.

LPS stimulated IL-1 β release and GSDME cleavage by *Nlrp3*^{CA/+};*Gsdmd*^{-/-} BMDMs

To examine how GSDMD deficiency affects IL-1 β secretion *in vitro*, its levels were measured after treatment of WT, *Nlrp3*^{CA/+} or *Nlrp3*^{CA/+};*Gsdmd*^{-/-} bone marrow-derived macrophages (BMDMs) primed with LPS and exposed to nigericin, which induces the assembly of the NLRP3 inflammasome (56). LPS alone induced IL-1 β secretion in *Nlrp3*^{CA/+} cells (Fig. 2A). Nigericin increased the release of IL-1 β by LPS-primed cells in the three genotypes, though this response was delayed in double mutant cells, reaching levels comparable to WT and *Nlrp3*^{CA/+} cells by 2 hours. We also assessed cell death by measuring the release of lactate dehydrogenase (LDH) into the cell supernatant. While LPS and nigericin were required for LDH release from WT BMDMs, endotoxin alone induced these responses in *Nlrp3*^{CA/+} and *Nlrp3*^{CA/+};*Gsdmd*^{-/-} cells, though this response was attenuated in double mutant cells and enhanced by nigericin in both genotypes (Fig. 2B). While GSDMs are the executioners of pyroptosis, mixed lineage kinase domain-like pseudokinase (MLKL) plays a critical role in the cell death necroptosis, the programmed form of necrosis. MLKL perforates the plasma cell membrane and executes necroptosis upon phosphorylation by receptor interacting serine/threonine kinase 3 (RIPK3) (68, 69). We determined whether MLKL was involved in the responses of *Nlrp3*^{CA/+};*Gsdmd*^{-/-} BMDMs. MLKL was not phosphorylated in *Nlrp3*^{CA/+};*Gsdmd*^{-/-} BMDMs treated with LPS or LPS plus nigericin, (fig. S2), suggesting that the delayed death of these cells was necroptosis-independent. Thus, IL-1 β secretion and pyroptosis are attenuated in *Nlrp3*^{CA/+};*Gsdmd*^{-/-} compared to WT and *Nlrp3*^{CA/+} BMDMs in response to NLRP3 inflammasome activators. However, these responses are undistinguishable among the three cell types where the NLRP3 inflammasome is persistently activated.

To study NLRP3 inflammasome signaling in GSDMD sufficient or insufficient cells, we treated WT, *Nlrp3*^{CA/+}, and *Nlrp3*^{CA/+};*Gsdmd*^{-/-} BMDMs with LPS in the absence or presence of nigericin. While the combination of LPS and nigericin was required for the formation of ASC specks, a readout of activated inflammasomes (fig. S3) and the cleavage of GSDMD and caspase-1 in WT BMDMs, LPS alone induced these responses in *Nlrp3*^{CA/+} and *Nlrp3*^{CA/+};*Gsdmd*^{-/-} cells (Fig. 2C; fig. S3), consistent with the constitutively activated state of NLRP3 (52). However, the combination of LPS and nigericin caused more GSDMD and caspase-1 cleavage than LPS alone in cells with constitutively active NLRP3 (Fig. 2C). Whenever caspase-1 was cleaved in these cells there was a faint caspase-8, -3 cleavage band. Although full length GSDME was easily visualized in WT and *Nlrp3*^{CA/+} BMDMs, cleavage of GSDME was not readily detected. However, in *Nlrp3*^{CA/+};*Gsdmd*^{-/-} cells, although basal levels of caspase-8, -3 and GSDME appeared similar to levels in WT or *Nlrp3*^{CA/+} BMDMs, cleaved caspase-8 (p18 fragment) and caspase-3 (p17 fragment), which are fully active, were more prominent and GSDME cleavage was readily detected (Fig. 2C). Neither GSDME nor caspase-8, -3 cleavage in *Nlrp3*^{CA/+};*Gsdmd*^{-/-} BMDMs required nigericin. Thus, in *Nlrp3*^{CA/+};*Gsdmd*^{-/-} cells, caspase-8, -3 and GSDME are activated by LPS.

GSDME was involved in IL-1 β and IL-18 secretion induced by LPS or TNF- α in *Nlrp3*^{CA/+};*Gsdmd*^{-/-} mice

To determine whether GSDMD-independent inflammation in LPS-treated mice might be due to GSDME activation, we first compared baseline and LPS-stimulated blood serum cytokines (IL-1 β , IL-18, IL-6, and CXCL1) in *Gsdme*^{-/-} and *Gsdmd*^{-/-};*Gsdme*^{-/-} animals bearing unmutated *Nlrp3*. Baseline cytokine levels were comparable between *Gsdme*^{-/-} and *Gsdmd*^{-/-};*Gsdme*^{-/-} mice and were similar to levels in WT animals (Fig. 3A). After LPS challenge, the IL-1 family cytokines were similarly elevated in *Gsdme*^{-/-} mice as in WT mice but did not increase in *Gsdmd*^{-/-};*Gsdme*^{-/-} animals. LPS induced elevated IL-6 and CXCL1 in all genotypes. Next, we measured IL-1 β levels in response to LPS or TNF- α in WT, *Nlrp3*^{CA/+}, *Nlrp3*^{CA/+};*Gsdmd*^{-/-}, and *Nlrp3*^{CA/+};*Gsdmd*^{-/-};*Gsdme*^{-/-} mice. *Nlrp3*^{CA/+};*Gsdme*^{-/-} mice were not generated since LPS-induced responses were not impaired in *Gsdme*^{-/-} animals (Fig. 3A). LPS or TNF- α induced IL-1 β production in WT, *Nlrp3*^{CA/+}, and *Nlrp3*^{CA/+};*Gsdmd*^{-/-} mice (Fig. 3B). Notably, IL-1 β levels were decreased in *Nlrp3*^{CA/+};*Gsdmd*^{-/-};*Gsdme*^{-/-} compared to *Nlrp3*^{CA/+};*Gsdmd*^{-/-} mice. These results suggest that GSDME participates in NLRP3 inflammasome signaling in states of GSDMD deficiency.

GSDME was cleaved in BMDMs lacking GSDMD and involved in IL-1 β and LDH release

To further examine the impact of GSDMD and GSDME deficiency on LPS plus nigericin induced pyroptosis and IL-1 β processing and release *in vitro*, WT, *Gsdmd*^{-/-}, *Gsdme*^{-/-}, and *Gsdmd*^{-/-};*Gsdme*^{-/-} BMDMs lacking constitutively activated NLRP3 were pretreated with LPS for 3 hours and then with nigericin for up to 4 hours. Within 20 minutes of adding nigericin, caspase-1, and -3 were cleaved in all 4 cell lines (Fig. 4A, and fig. S4, A and B). Similar to our findings in Fig. 3A in *Nlrp3*^{CA/+} BMDMs, in cells bearing unmutated *Nlrp3* treated with LPS and nigericin, GSDMD was cleaved in WT and *Gsdme*^{-/-} BMDMs. Consistent with the notion that caspase-8 directly activates caspase-3, the catalytically active caspase-8 p18 and caspase-3 p17 fragments were both more prominent in cells lacking GSDMD. GSDME cleavage was detected only in *Gsdmd*^{-/-} cells. GSDMD and GSDME cleavage was detected at the same time as caspase activation. Since GSDME was not readily cleaved in WT BMDMs, the time-dependent decline of its levels in WT cells was likely secondary to pyroptosis. Thus, GSDME cleavage occurred after NLRP3 inflammasome activation not only in *Nlrp3*^{CA/+};*Gsdmd*^{-/-} BMDMs (Fig. 3A) but also *Gsdmd*^{-/-} BMDMs.

Next, we examined whether caspase-1 was required to activate caspase-3 and GSDME by treating caspase-1 deficient BMDMs with LPS and nigericin. Consistent with previous reports (70), LPS and nigericin activated caspase-3, and promoted the generation of the GSDMD p10 fragment in *Casp1*^{-/-} BMDMs, although caspase-3 and GSDMD processing were delayed compared to caspase-1 sufficient cells (fig. S4C). GSDME cleavage was detected in *Casp1*^{-/-} BMDMs at the same time as fully processed caspase-3. Thus, although the maturation of caspase-1 and GSDMD was unperturbed by GSDME deficiency, NLRP3 inflammasome activation forced GSDME processing in cells lacking either caspase-1 or GSDMD.

We examined the extent to which GSDME mediated IL-1 β and LDH release in GSDMD deficient cells. Although LPS-primed *Gsdmd*^{-/-} BMDMs did not release IL-1 β or LDH at early time-points up to 1 hour after nigericin addition, they were as active as WT cells in secreting IL-1 β and releasing LDH at later time-points (Fig. 4, B and C) and in dose-dependent manner (fig. S4D). Loss of GSDME did not affect IL-1 β and pyroptosis, but these readouts were significantly impaired, but not abrogated, in *Gsdmd*^{-/-};*Gsdme*^{-/-} BMDMs (Fig. 4B). Likewise, LDH release was delayed and IL-1 β levels were nearly undetectable in *caspase-1*^{-/-} BMDMs (fig. S4E), suggesting that cleaved and secreted IL-1 β but not intracellular pro-IL-1 β was detected in the supernatants of *Nlrp3*^{CA/+};*Gsdmd*^{-/-} (Fig. 3B) or *Gsdmd*^{-/-} (Fig. 4B) BMDM cultures. GSDME cleavage and IL-1 β secretion in *Gsdmd*^{-/-} and *Nlrp3*^{CA/+};*Gsdmd*^{-/-} BMDMs induced by LPS and nigericin were inhibited by the pan caspase inhibitor, zVAD (fig. S5, A and B), results that were consistent with the reported cleavage of GSDME by caspase-3 (22-24). zVAD failed to consistently inhibited LDH release (fig. S5C), and caspase-11 was not activated in these experimental conditions where LPS was added extracellularly (fig. S6A). As a result, GSDME processing (fig. S6A), IL-1 β secretion and LDH release (fig. S6B) were comparable between WT and *caspase-11*^{-/-} BMDMs.

Finally, we studied the effects of LPS on WT, *Nlrp3*^{CA/+}, *Nlrp3*^{CA/+};*Gsdmd*^{-/-}, and *Nlrp3*^{CA/+};*Gsdmd*^{-/-};*Gsdme*^{-/-} BMDMs. LPS alone did not stimulate IL-1 β secretion (Fig. 5A) and LDH release (Fig. 5B) in WT cells, as expected. However, LPS induced IL-1 β secretion and LDH release in *Nlrp3*^{CA/+}; howeverm the inhibition of this response was transient in *Nlrp3*^{CA/+};*Gsdmd*^{-/-} BMDMs (up to 9 hours) and it was sustained in *Nlrp3*^{CA/+};*Gsdmd*^{-/-};*Gsdme*^{-/-} BMDMs up to 24 hours (Fig. 5A and B). Thus, the release of IL-1 β and LDH was persistently inhibited, though not completely eradicated, in *Gsdmd*^{-/-};*Gsdme*^{-/-} BMDMs subjected to sustained NLRP3 inflammasome activation.

CuET inhibited GSDMD, GSDME, and IL-1 β maturation and LDH release

Disulfiram and its active metabolite, bis(diethyldithiocarbamate)-copper (CuET), antagonize GSDMD pore-forming activity but have not been reported to inhibit GSDME pore formation (64). To investigate whether these compounds might inhibit GSDMD-independent pyroptosis, WT, *Gsdmd*^{-/-}, *Gsdme*^{-/-}, and *Gsdmd*^{-/-};*Gsdme*^{-/-} BMDMs were treated with LPS for 3 hours and then CuET or vehicle for 1 hour followed by an additional 3 hours of incubation with nigericin. In the absence of CuET, GSDMD was cleaved in WT and *Gsdme*^{-/-} BMDMs (Fig. 6A) and caspase-1 deficient BMDMs (fig. S7A), consistent with the results shown in Fig. 4. While GSDME was cleaved only in *Gsdmd*^{-/-} cells, caspase-1 and caspase-3 were cleaved in all cell lines. However, although the full-length caspase protein bands sharply decreased, the signals of their cleaved fragments were faint (Fig. 6A), presumably because they might have been released to the extracellular milieu during pyroptosis (71-73), which was maximal in cells treated with nigericin for 2 hours. GSDMD, GSDME, and caspase-1 cleavage was consistently inhibited by CuET, in a dose-dependent manner (Fig. 6A, and fig. S7A). The band for cleaved caspase-3 was more prominent in CuET-treated than untreated WT, *Gsdmd*^{-/-}, and *Gsdme*^{-/-} BMDMs. CuET inhibited the release of IL-1 β and LDH in all cell genotypes (Fig. 6, B and C, and fig. S7B), but was less efficacious in *Gsdmd*^{-/-};*Gsdme*^{-/-} BMDMs, in which cytokine release and pyroptosis

were attenuated (Fig. 6, B and C). Disulfiram and CuET both inhibited IL-1 β and LDH release in WT BMDMs with comparable dose response curves (fig. S7C-F). Thus, CuET inhibits the maturation of both GSDMD and GSDME, inhibiting both GSDMD-dependent and -independent pyroptosis and IL-1 β release.

CuET inhibited NLRP3 inflammasome-dependent but not -independent responses

The ability of CuET to inhibit the cleavage of GSDMD and GSDME downstream of caspase-1 and caspase-3, respectively, raises concerns that this compound may act as a pan caspase inhibitor. To determine whether CuET inhibits inflammasome-independent GSDME-maturation, BMDMs were treated with raptinal or TNF- α and 5Z-7-oxozeanol (5Z-7, a TGF- β -activated kinase-1 inhibitor) in the presence or absence of CuET; both treatments are known to activate caspase-3 and GSDME-dependent pyroptosis independently of any inflammasome (23, 74). CuET did not inhibit the cleavage of GSDMD (to p10 GSDMD), GSDME, or caspase-3 induced by raptinal or TNF- α and 5Z-7 (Fig. 7, A and B, and fig. S8A) and if anything appeared to enhance their cleavage in response to these stimuli (Fig. 7B). To determine why CuET inhibited the cleavage of these proteins in response to NLRP3 inflammasome activation but not apoptotic stimuli, we analyzed its effects on NF- κ B and MAPK activation. CuET had no effect on LPS stimulated phosphorylation of I κ B α , NF- κ B/p65, and p38 MAPK (fig. S8B). We also analyzed CuET effects on LPS plus nigericin-induced inflammasome activation by measuring the formation of ASC specks, a key step in inflammasome assembly and activation, using WT BMDMs expressing fluorescent *Asc-citrine*. To minimize potential effects of CuET on inflammasome priming signals, the drug was added to LPS-primed cells and immediately followed by adding nigericin. The formation of ASC specks was significantly inhibited by CuET (Fig. 7C). These results suggest that CuET inhibits NLRP3 inflammasome activation, but not GSDME, caspase-3 or LPS-induced NF- κ B or MAPK activation.

CuET prevented inflammasomopathy in *Nlrp3*^{CA/+} mice

Based on its *in vitro* potency in inhibiting the release of cytokines and pyroptosis, CuET should improve the disease outcomes of *Nlrp3*^{CA/+} mice. To test this idea, CuET was intraperitoneally injected to 10-day-old pups, once every 2 days (75). CuET significantly improved the survival rate of *Nlrp3*^{CA/+} mice (fig. S9A) and reduced splenomegaly in these mice (fig. S9B). Despite improved survival, treated- *Nlrp3*^{CA/+} mice still showed early mortality, likely due to the severe inflammation already activated before treatment was initiated. To control the onset of this possible inflammation, we leveraged the *Nlrp3*^{+/fl(D301N);Cre-ERTM model for postnatal inducible activation of the NLRP3^{CA} (iNLRP3^{CA}) inflammasome in adult mice to test the efficacy of prophylactically administered CuET. Three-month-old mice were injected with tamoxifen 3 times/week for 2 weeks. Vehicle or CuET were injected 2 days before starting tamoxifen and continued 3 times/week for 6 weeks. *iNlrp3*^{CA/+} mice all survived but developed cachexia, splenomegaly, leukocytosis and neutrophilia, which were significantly attenuated by CuET (Fig. 8A). CuET prevented inflammation in the liver and the disorganization of splenic architecture in *iNlrp3*^{CA/+} mice as assessed by H & E staining and had no apparent effect on these tissues in WT controls (Fig. 8B, and fig. S9C). Although the effects of CuET were not analyzed in *Nlrp3*^{CA/+}; *Gsdmd*^{-/-} mice due to the limited number of}

animals for *in vivo* studies, we determined its actions on these cells *in vitro*. We found that CuET inhibited IL-1 β secretion and LDH release in WT and *Nlrp3^{CA/+};Gsdmd^{-/-}* BMDMs (fig. S10). Thus, our findings show that CuET-treated *Nlrp3^{CA/+}* mice phenocopy *Nlrp3^{CA/+};Gsdmd^{-/-};Gsdme^{-/-}* mice, consistent with the ability of this drug to inhibit GSDMD and GSDME cleavage (Fig. S11).

DISCUSSION

Nlrp3^{CA/+} (NOMID) mice die perinatally because of severe systemic multi-organ complications driven by excessive blood levels of IL-1 β and IL-18 (52, 76). *Nlrp3^{CA/+}* mice lacking GSDMD (*Nlrp3^{CA/+};Gsdmd^{-/-}* mice) grew and aged normally and are fertile. Consistent with these observations, ablation of GSDMD reduces inflammation and improves disease outcomes in mouse models of NOMID, sepsis, Familial Mediterranean Fever (FMF), and experimental autoimmune encephalitis (14, 56, 57, 77). However, when stressed by exposure to LPS, *Nlrp3^{CA/+};Gsdmd^{-/-}* mice unexpectedly secreted high amounts of IL-1 β and IL-18. The combination of these inflammatory stimuli with constitutively active NLRP3 overwhelmed the protection provided by GSDMD or caspase-1 deficiency to various extents, rewiring signaling cascades through caspase-3 and GSDME likely to cause pyroptosis (22, 25). These observations suggest that therapeutic inhibition of GSDMD may not be sufficient to prevent complications such as those associated with infections, which have the potential to activate not only GSDMD but also GSDME. This scenario can be tested preclinically by assessing the consequences of infections or injuries in NOMID or FMF mice lacking GSDMD, which can be viewed as animals with an underlying inflammatory condition. Thus, though apparently normal in homeostatic conditions, *Nlrp3^{CA/+};Gsdmd^{-/-}* mice are vulnerable to stressful insults.

Both *Nlrp3^{CA/+};Gsdmd^{-/-}* BMDMs and *Gsdmd^{-/-}* BMDMs produced IL-1 β and underwent pyroptosis in response to LPS, although these responses were delayed in both cell lines compared to WT cells, occurring only upon sustained exposure to NLRP3 inflammasome activators. The responsiveness of *Gsdmd^{-/-}* cells to LPS *in vitro* suggested that exposure of GSDMD-deficient mice to endotoxin for a long period may lead to significant IL-1 β and IL-18 secretion. Consistent with this, a small proportion of *Gsdmd^{-/-}* mice die upon LPS-challenge (14, 64). Pyroptosis and cytokine release by GSDMD or caspase-1 deficient cells positively correlated with caspase-3 and GSDME activation and were significantly suppressed in *Nlrp3^{CA/+};Gsdmd^{-/-};Gsdme^{-/-}* cells and *Gsdmd^{-/-};Gsdme^{-/-}* cells, suggesting that caspase-3 activation of GSDME was largely responsible for inflammatory death when NLRP3 was activated but the canonical caspase-1-GSDMD pathway was not available. Consistent with our findings on GSDM complementation, a recent study reported that the TLR1/TLR2 agonist Pam3CSK4 promotes the release of IL-1 α by caspase-1 deficient macrophages through GSDME conduits (28). In our study, caspase-3 activation was enhanced by GSDMD or caspase-1 genetic deficiency. We did not explore the mechanism responsible for increased caspase-8 and caspase-3 activation in these settings, but one possibility was that caspase-8 was efficiently recruited to the NLRP3 complex when caspase-1 or GSDMD was absent and very potent at processing caspase-3, which in turn activated GSDME. It is worth noting that there was some residual IL-1 β release and pyroptosis in chronically activated *Nlrp3^{CA/+};Gsdmd^{-/-};Gsdme^{-/-}* cells and

Gsdmd^{-/-}; *Gsdme*^{-/-} BMDMs, suggesting that another GSDMD and GSDME independent inflammation pathway may be activated downstream of NLRP3, potentially involving another caspase and/or another gasdermin. From our study it remains uncertain whether cytokines are secreted through GSDME pores in the setting of caspase-1 or GSDMD deficiency or are released when the cell membrane is grossly disrupted and LDH is released, as was recently reported (82, 83). Taken together, these results suggest that macrophages have more than one salvage mechanism to ensure that signals transmitted by inflammasome activators result in inflammation. However, outcomes such as temperature changes and immune cell recruitment to tissues in LPS-treated *Nlrp3*^{CA/+}; *Gsdmd*^{-/-}; *Gsdme*^{-/-} mice were not assessed in this study, but are themes of interest for future investigations.

Drug discovery and repurposing efforts have identified the FDA-approved drugs dimethyl fumarate and disulfiram as GSDMD inhibitors (58, 64). Covalent modification of Cys191 in human and Cys192 in mouse is the proposed main mechanism through which disulfiram inhibits GSDMD pore-forming activity, although dimethyl fumarate likely works through another mechanism (64). Here, we report that the disulfiram metabolite CuET exhibited remarkable efficacy in the *Nlrp3*^{CA} inflammasomopathy model as it prevented systemic inflammation and the damage to the liver and spleen. Mechanistically, we found that CuET suppressed cytokine secretion and pyroptosis caused by both GSDMD and GSDME. However, CuET inhibited GSDME cleavage and pyroptosis in cells stimulated with NLRP3 inflammasome activators but not apoptotic stimuli. These results ruled out GSDME as the major direct target of CuET inhibitory actions, a view that was consistent with the compound's ability to inhibit the formation of ASC specks. Although, as far as we are aware, direct inhibition of GSDME pore formation by disulfiram has never been measured, Cys191/192 is not conserved in mouse GSDME and therefore disulfiram is not predicted to be a potent regulator of GSDME. However, as a cysteine-reactive drug, disulfiram has the potential to inactivate other enzymes, including the caspase cysteine proteases and other proteins with reactive cysteines that are modulated by cellular redox status, which include the NLRP3 inflammasome (84). When a potent drug target such as GSDMD is not present, disulfiram may switch to inhibit other less reactive substrates, a scenario that may explain the inhibitory effects of CuET in cell lacking GSDMD and GSDME. However, we currently have limited knowledge on the selectivity profile of CuET, thus future studies will need to investigate how it inhibits ASC polymerization and whether it antagonizes other early steps of inflammasome signaling.

This study revealed that ablation of GSDMD in *Nlrp3*^{CA/+} mice did not prevent these animals from producing excessive levels of IL-1 β and IL-18 in response to inflammatory challenges. Importantly, the disease severity in *Nlrp3*^{CA/+} mice was remarkably reduced by CuET, a drug that interferes directly or indirectly with both GSDMD-dependent and independent inflammation. Our findings suggest that disulfiram might be worth testing in CAPS patients for whom existing therapies that inhibit IL-1 or other inflammatory cytokines do not adequately suppress disease symptoms.

MATERIALS AND METHODS

Study design

The objective of this study was to determine the responses of the seemingly normal *Gsdmd*^{-/-} mice expressing constitutive active NLRP3 – yet viewed as animals with an underlying inflammatory condition – to inflammatory stimuli (e.g., LPS, TNF- α). To achieve this goal, we used various strategies, including genetic and pharmacological manipulation, biochemical, histology, and immunostaining approaches.

Animals

Casp1^{-/-} were kindly provided by Dr. Thirumala-Devi Kanneganti (St. Jude Children's Research Hospital). *Cre-ER*TM (B6.Cg-Tg(CAG-cre/Esr1*)5Amc/J) mice and *Isozyme M-Cre* mice were purchased from The Jackson Laboratory (Sacramento, CA). *Nlrp3*^{fl(D301N)/+} mice were kindly provided by Dr. Hal Hoffman (University of California, San Diego), and have been previously described (52, 54, 85). *Nlrp3*^{CA/+} mice with constitutive activation of NLRP3 in myeloid cells driven by *Isozyme M-Cre* have been previously described (54). *Cre-ER*TM mice and *Nlrp3*^{fl(D301N)/+} mice were crossed to generate *Nlrp3*^{fl(D301N)/+;Cre-ER}TM mice and *Cre-ER*TM mice. Injection of tamoxifen (i.p., 75 mg/kg body weight; Sigma-Aldrich) to *Nlrp3*^{fl(D301N)/+;Cre-ER}TM mice and *Cre-ER*TM mice to yield inducible *Nlrp3*^{CA} (*iNlrp3*^{CA}) mice and control mice, respectively, has been previously described (85). *Gsdmd*^{-/-} mice were kindly provided by Dr. V. M. Dixit (Genentech, South San Francisco, CA). *Asc-citrine* and *Gsdme*^{-/-} mice were purchased from The Jackson Laboratory (Sacramento, CA). All mice were on the C57BL6J background and mouse genotyping was performed by PCR. All procedures were approved by the Institutional Animal Care and Use Committee of Washington University School of Medicine in St. Louis.

Administration of drugs, LPS, and TNF- α

Mice were i.p. injected with CuET (TCI America, OR) (1 mg/kg) formulated in sesame oil (0.2 mg/ml) or vehicle, once every other day, 3 times per week. Ten day-old *Nlrp3*^{CA/+} mice were treated with vehicle or CuET for 9 weeks; 12-week-old *iNlrp3*^{CA/+} and control mice were treated with vehicle or CuET 3 times/week for 6 weeks. For LPS challenge experiments, WT, *Gsdmd*^{-/-}, *Gsdme*^{-/-}, *Gsdmd*^{-/-};*Gsdme*^{-/-}, *Nlrp3*^{CA/+}, *Nlrp3*^{CA/+};*Gsdmd*^{-/-} and *Nlrp3*^{CA/+};*Gsdmd*^{-/-};*Gsdme*^{-/-} mice were i.p. injected with 15 mg/kg LPS (*Escherichia coli* O111:B4, Sigma, MO). Mice were i.p. injected with 0.5 mg/kg TNF- α (Biolegend, CA).

Serum cytokine assay

Blood was collected by cardiac puncture 6 hours or 2 hours after LPS or TNF- α challenge, and was allowed to clot at room temperature. Serum obtained after centrifugation at 2,000 x g for 10 minutes was used for determinations of cytokine and chemokine levels by V-PLEX Plus Proinflammatory Panel1 Mouse Kit (Meso Scale Diagnostics, MD), except IL-18, which was analyzed by enzyme linked immunosorbent assay (ELISA) kit (Sigma, MO).

Cell cultures

BMDMs were obtained by culturing mouse bone marrow cells in culture media containing a 1:10 dilution of supernatant from the fibroblastic cell line CMG 14-12 as a source of macrophage colony-stimulating factor (86), a mitogenic factor for BMDMs, for 4-5 days in a 15-cm dish as previously described (85). Briefly, nonadherent cells were removed by vigorous washes with PBS, and adherent BMDMs were detached with trypsin-EDTA and cultured in culture media containing a 1:10 dilution of CMG for various experiments.

For all *in vitro* pharmacology experiments except otherwise specified, cells were pre-treated with vehicle (0.1% DMSO, final concentration) or inhibitors (in 0.1% DMSO, final concentration) for 1 hour before stimulation with the indicated ligand or ligands. Protein expression was analyzed by ELISA or Western blot as described below. To activate the NLRP3 inflammasome, BMDMs were plated at 10^4 cells per well on a 96-well plate or 10^6 cells per well on a 6-well plate overnight. Cells were primed with LPS and then with 15 μ M nigericin (AdipoGen) as indicated, and conditioned media were collected for the analysis of IL-1 β and LDH.

Histology

Tissue samples were processed as described previously (85). In brief, liver, and spleen were fixed in 10% formalin overnight. Fixed tissues were embedded in paraffin, sectioned at 5- μ m thicknesses, and mounted on glass slides. The sections were stained with H&E as described previously (85). Photographs were taken using ZEISS microscopy (Carl Zeiss Industrial Metrology, MN).

Peripheral blood analyses

Mouse blood was collected by cardiac puncture in the EDTA-containing tubes. Complete blood counts were performed by the Washington University School of Medicine as previously described (54).

Western blot analysis

Cell extracts were prepared by lysing cells with RIPA buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.5% NaDOAc, 0.1% SDS, and 1.0% NP-40) plus phosphatase and protease inhibitors (2 mM NaVO₄, 10 mM NaF, and 1 mM PMSF) and Complete protease inhibitor cocktail (Roche, CA). For tissue extracts, liver tissues were homogenized and lysed with RIPA buffer containing phosphatase and protease inhibitors. Protein concentrations were determined by the Bio-Rad Laboratories method, and equal amounts of proteins were subjected to SDS-PAGE gels (12%) as previously described (56). Proteins were transferred onto nitrocellulose membranes and incubated with antibodies against GSDMD (1:1,000; Abcam, MA), GSDME (1:1,000; Abcam, MA), caspase-1 (1:1,000; Abcam, MA), caspase-3 (1:1,000; Cell Signaling Technologies, MA), p38 MAPK (1:1,000; Cell Signaling Technologies, MA), β -actin (1:2,000; Santa Cruz Biotechnology, TX), p65/p-p65 (1:1,000; Cell Signaling Technologies, MA), I κ B α /p-I κ B α (1:1,000; Cell Signaling Technologies, MA), or pMLKL (1:1,000; Cell Signaling Technologies, MA) overnight at 4°C followed by incubation for 1 hour with secondary goat anti-mouse IRDye 800 (Thermo Fisher Scientific, MA) or goat anti-rabbit Alexa Fluor 680 (Thermo Fisher Scientific, MA), respectively. The

results were visualized using the Odyssey infrared imaging system (LI-COR Biosciences, NE).

LDH assay and IL-1 β ELISA

Cell death was assessed by the release of LDH in conditioned medium using LDH Cytotoxicity Detection Kit (TaKaRa, CA). IL-1 β levels in conditioned media were measured by an ELISA kit (eBiosciences, NY).

ASC specks assay

Asc-citrine, WT, and *Nlrp3*^{CA/+}; *Gsdmd*^{-/-} BMDMs were plated at 10⁴ cells per well on a 16-well glass plate overnight. Cells were primed with LPS for 3 hours and pretreated or not with CuET for 15 minutes before adding 15 μ M nigericin (AdipoGen, CA) for 30 minutes. Cells were washed with PBS and fixed with 4% polyformalin buffer for 10 minutes at room temperature. For immunostaining, WT and *Nlrp3*^{CA/+}; *Gsdmd*^{-/-} BMDMs were permeabilized with 0.2% Triton in PBS for 20 minutes, blocked with 0.2% Triton, 1% BSA, and CD61 antibody (1:1000; Alexa Fluor 647, BD, NJ) in PBS for 30 minutes, and were incubated with ASC antibody (1:1000; clone 2EI-7, EMD Millipore, MA) overnight at 4°C in blocking buffer, followed by incubation with secondary antibody (Alexa Fluor 594, Life Technologies) for 30 minutes. Cells were counterstained with Fluoro-gel II containing DAPI (Fluoro-Gel, Fisher Scientific Intl INC, PA). *Asc-citrine* photographs were taken using ZEISS microscopy (Carl Zeiss Industrial Metrology, MN). ASC immunostaining images were taken using a Leica inverted microscope with a TCS SPEII confocal module and processed using LAS X software (Leica Microsystems Inc, IL). Quantification of ASC specks was carried out using ImageJ.

Statistical analysis

Statistical analysis was performed using the Student's t test, one-way ANOVA with Tukey's multiple comparisons test, or two-way ANOVA with Tukey's multiple comparisons test, Dunnett's multiple comparisons test, or Sidak's multiple comparisons test as well as the Log-rank (Mantel-Cox) test for comparison of survival curves using the GraphPad Prism 8.0 Software. Values are expressed as mean \pm SEM or means \pm SD, as indicated. * $p < 0.05$ was considered statistically significant.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We want to thank Dr. Deborah J. Veis for critical reading of this manuscript.

Funding:

This work was supported by NIH/NIAMS AR068972 and AR076758 grants to G.M. Y.A.-A. was supported by NIH grants AR049192, AR054326, AR072623 and by a grant #85160 from the Shriners Hospital for Children.

REFERENCES AND NOTES

1. Schroder K, Tschopp J, The inflammasomes. *Cell* 140, 821–832 (2010). [PubMed: 20303873]
2. Guo H, Callaway JB, Ting JP, Inflammasomes: mechanism of action, role in disease, and therapeutics. *Nature medicine* 21, 677–687 (2015).
3. Broz P, Dixit VM, Inflammasomes: mechanism of assembly, regulation and signalling. *Nature reviews. Immunology* 16, 407–420 (2016).
4. Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, Zhuang Y, Cai T, Wang F, Shao F, Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. *Nature* 526, 660–665 (2015). [PubMed: 26375003]
5. Ding J, Wang K, Liu W, She Y, Sun Q, Shi J, Sun H, Wang D-C, Shao F, Pore-forming activity and structural autoinhibition of the gasdermin family. *Nature* 535, 111–116 (2016). [PubMed: 27281216]
6. Evavold CL, Ruan J, Tan Y, Xia S, Wu H, Kagan JC, The Pore-Forming Protein Gasdermin D Regulates Interleukin-1 Secretion from Living Macrophages. *Immunity* 48, 35–44.e36 (2018). [PubMed: 29195811]
7. He W.-t., Wan H, Hu L, Chen P, Wang X, Huang Z, Yang Z-H, Zhong C-Q, Han J, Gasdermin D is an executor of pyroptosis and required for interleukin-1 β secretion. *Cell Research* 25, 1285–1298 (2015). [PubMed: 26611636]
8. Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, Lieberman J, Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. *Nature* 535, 153–158 (2016). [PubMed: 27383986]
9. Man SM, Karki R, Kanneganti T-D, Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. *Immunological reviews* 277, 61–75 (2017). [PubMed: 28462526]
10. Shi J, Gao W, Shao F, Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death. *Trends in Biochemical Sciences* 42, 245–254 (2017). [PubMed: 27932073]
11. Mira JC, Gentile LF, Mathias BJ, Efron PA, Brakenridge SC, Mohr AM, Moore FA, Moldawer LL, Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome. *Critical care medicine* 45, 253–262 (2017). [PubMed: 27632674]
12. Hoffman HM, Brydges SD, Genetic and molecular basis of inflammasome-mediated disease. *The Journal of biological chemistry* 286, 10889–10896 (2011). [PubMed: 21296874]
13. de Jesus AA, Canna SW, Liu Y, Goldbach-Mansky R, Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling. *Annual review of immunology* 33, 823–874 (2015).
14. Kayagaki N, Stowe IB, Lee BL, O'Rourke K, Anderson K, Warming S, Cuellar T, Haley B, Roose-Girma M, Phung QT, Liu PS, Lill JR, Li H, Wu J, Kummerfeld S, Zhang J, Lee WP, Snipas SJ, Salvesen GS, Morris LX, Fitzgerald L, Zhang Y, Bertram EM, Goodnow CC, Dixit VM, Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. *Nature* 526, 666–671 (2015). [PubMed: 26375259]
15. Kambara H, Liu F, Zhang X, Liu P, Bajrami B, Teng Y, Zhao L, Zhou S, Yu H, Zhou W, Silberstein LE, Cheng T, Han M, Xu Y, Luo HR, Gasdermin D Exerts Anti-inflammatory Effects by Promoting Neutrophil Death. *Cell reports* 22, 2924–2936 (2018). [PubMed: 29539421]
16. Karmakar M, Minns M, Greenberg EN, Diaz-Aponte J, Pestonjamas K, Johnson JL, Rathkey JK, Abbott DW, Wang K, Shao F, Catz SD, Dubyak GR, Pearlman E, N-GSDMD trafficking to neutrophil organelles facilitates IL-1 β release independently of plasma membrane pores and pyroptosis. *Nature communications* 11, 2212 (2020).
17. Chen KW, Monteleone M, Boucher D, Sollberger G, Ramnath D, Condon ND, von Pein JB, Broz P, Sweet MJ, Schroder K, Noncanonical inflammasome signaling elicits gasdermin D-dependent neutrophil extracellular traps. *Science immunology* 3, (2018).
18. Burgener SS, Leborgne NGF, Snipas SJ, Salvesen GS, Bird PI, Benarafa C, Cathepsin G Inhibition by Serpinb1 and Serpinb6 Prevents Programmed Necrosis in Neutrophils and Monocytes and Reduces GSDMD-Driven Inflammation. *Cell reports* 27, 3646–3656.e3645 (2019). [PubMed: 31216481]

19. Chen KW, Demarco B, Heilig R, Shkarina K, Boettcher A, Farady CJ, Pelczar P, Broz P, Extrinsic and intrinsic apoptosis activate pannexin-1 to drive NLRP3 inflammasome assembly. *Embo j* 38, (2019).
20. Sarhan J, Liu BC, Muendlein HI, Li P, Nilson R, Tang AY, Rongvaux A, Bunnell SC, Shao F, Green DR, Poltorak A, Caspase-8 induces cleavage of gasdermin D to elicit pyroptosis during *Yersinia* infection. *Proceedings of the National Academy of Sciences of the United States of America* 115, E10888–e10897 (2018). [PubMed: 30381458]
21. Orning P, Weng D, Starheim K, Ratner D, Best Z, Lee B, Brooks A, Xia S, Wu H, Kelliher MA, Berger SB, Gough PJ, Bertin J, Proulx MM, Goguen JD, Kayagaki N, Fitzgerald KA, Lien E, Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death. *Science (New York, N.Y.)* 362, 1064–1069 (2018).
22. Rogers C, Fernandes-Alnemri T, Mayes L, Alnemri D, Cingolani G, Alnemri ES, Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death. *Nature communications* 8, 14128 (2017).
23. Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu X, Junqueira C, Meza-Sosa KF, Mok TMY, Ansara J, Sengupta S, Yao Y, Wu H, Lieberman J, Gasdermin E suppresses tumour growth by activating anti-tumour immunity. *Nature* 579, 415–420 (2020). [PubMed: 32188940]
24. Rogers C, Erkes DA, Nardone A, Aplin AE, Fernandes-Alnemri T, Alnemri ES, Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. *Nature communications* 10, 1689 (2019).
25. Wang Y, Gao W, Shi X, Ding J, Liu W, He H, Wang K, Shao F, Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. *Nature* 547, 99–103 (2017). [PubMed: 28459430]
26. Yu J, Li S, Qi J, Chen Z, Wu Y, Guo J, Wang K, Sun X, Zheng J, Cleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells. *Cell Death & Disease* 10, 193 (2019). [PubMed: 30804337]
27. Tsuchiya K, Nakajima S, Hosojima S, Thi Nguyen D, Hattori T, Manh Le T, Hori O, Mahib MR, Yamaguchi Y, Miura M, Kinoshita T, Kushiyama H, Sakurai M, Shiroishi T, Suda T, Caspase-1 initiates apoptosis in the absence of gasdermin D. *Nature communications* 10, 2091 (2019).
28. Aizawa E, Karasawa T, Watanabe S, Komada T, Kimura H, Kamata R, Ito H, Hishida E, Yamada N, Kasahara T, Mori Y, Takahashi M, GSDME-Dependent Incomplete Pyroptosis Permits Selective IL-1 α Release under Caspase-1 Inhibition. *iScience* 23, 101070 (2020). [PubMed: 32361594]
29. Liu Y, Fang Y, Chen X, Wang Z, Liang X, Zhang T, Liu M, Zhou N, Lv J, Tang K, Xie J, Gao Y, Cheng F, Zhou Y, Zhang Z, Hu Y, Zhang X, Gao Q, Zhang Y, Huang B, Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. *Science immunology* 5, (2020).
30. Tixeira R, Shi B, Parkes MAF, Hodge AL, Caruso S, Hulett MD, Baxter AA, Phan TK, Poon IKH, Gasdermin E Does Not Limit Apoptotic Cell Disassembly by Promoting Early Onset of Secondary Necrosis in Jurkat T Cells and THP-1 Monocytes. *Frontiers in immunology* 9, 2842 (2018). [PubMed: 30564238]
31. Lee BL, Mirrashidi KM, Stowe IB, Kummerfeld SK, Watanabe C, Haley B, Cuellar TL, Reichelt M, Kayagaki N, ASC- and caspase-8-dependent apoptotic pathway diverges from the NLRC4 inflammasome in macrophages. *Scientific reports* 8, 3788 (2018). [PubMed: 29491424]
32. Heilig R, Dilucca M, Boucher D, Chen KW, Hancz D, Demarco B, Shkarina K, Broz P, Caspase-1 cleaves Bid to release mitochondrial SMAC and drive secondary necrosis in the absence of GSDMD. *Life science alliance* 3, (2020).
33. Vince JE, De Nardo D, Gao W, Vince AJ, Hall C, McArthur K, Simpson D, Vijayaraj S, Lindqvist LM, Bouillet P, Rizzacasa MA, Man SM, Silke J, Masters SL, Lessene G, Huang DCS, Gray DHD, Kile BT, Shao F, Lawlor KE, The Mitochondrial Apoptotic Effectors BAX/BAK Activate Caspase-3 and -7 to Trigger NLRP3 Inflammasome and Caspase-8 Driven IL-1 β Activation. *Cell reports* 25, 2339–2353.e2334 (2018). [PubMed: 30485804]
34. Shen HH, Yang YX, Meng X, Luo XY, Li XM, Shuai ZW, Ye DQ, Pan HF, NLRP3: A promising therapeutic target for autoimmune diseases. *Autoimmunity reviews* 17, 694–702 (2018). [PubMed: 29729449]

35. Zambetti LP, Mortellaro A, NLRPs, microbiota, and gut homeostasis: unravelling the connection. *The Journal of pathology* 233, 321–330 (2014). [PubMed: 24740681]
36. Zhen Y, Zhang H, NLRP3 Inflammasome and Inflammatory Bowel Disease. *Frontiers in immunology* 10, 276 (2019). [PubMed: 30873162]
37. Spel L, Martinon F, Inflammasomes contributing to inflammation in arthritis. *Immunological reviews* 294, 48–62 (2020). [PubMed: 31944344]
38. Jäger E, Murthy S, Schmidt C, Hahn M, Strobel S, Peters A, Stäubert C, Sungur P, Venus T, Geisler M, Radusheva V, Raps S, Rothe K, Scholz R, Jung S, Wagner S, Pierer M, Seifert O, Chang W, Estrela-Lopis I, Raulien N, Krohn K, Sträter N, Hoepfener S, Schöneberg T, Rossol M, Wagner U, Calcium-sensing receptor-mediated NLRP3 inflammasome response to calciprotein particles drives inflammation in rheumatoid arthritis. *Nature communications* 11, 4243 (2020).
39. Alippe Y, Mbalaviele G, Omnipresence of inflammasome activities in inflammatory bone diseases. *Seminars in immunopathology* 41, 607–618 (2019). [PubMed: 31520179]
40. Zhuang T, Liu J, Chen X, Zhang L, Pi J, Sun H, Li L, Bauer R, Wang H, Yu Z, Zhang Q, Tomlinson B, Chan P, Zheng X, Morrissey E, Liu Z, Reilly M, Zhang Y, Endothelial Foxp1 Suppresses Atherosclerosis via Modulation of Nlrp3 Inflammasome Activation. *Circulation research* 125, 590–605 (2019). [PubMed: 31318658]
41. Grebe A, Hoss F, Latz E, NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. *Circulation research* 122, 1722–1740 (2018). [PubMed: 29880500]
42. Eisenbarth SC, Flavell RA, Innate instruction of adaptive immunity revisited: the inflammasome. *EMBO molecular medicine* 1, 92–98 (2009). [PubMed: 20049709]
43. Renaudin F, Orliaguet L, Castelli F, Fenaille F, Prignon A, Alzaid F, Combes C, Delvaux A, Adimy Y, Cohen-Solal M, Richette P, Bardin T, Riveline JP, Venticlef N, Lioté F, Campillo-Gimenez L, Ea HK, Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1 β activation on macrophages. *Annals of the rheumatic diseases* 79, 1506–1514 (2020). [PubMed: 32699039]
44. Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, Stamp LK, Gout. *Nature reviews. Disease primers* 5, 69 (2019).
45. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J, Gout-associated uric acid crystals activate the NALP3 inflammasome. *Nature* 440, 237–241 (2006). [PubMed: 16407889]
46. Ding S, Xu S, Ma Y, Liu G, Jang H, Fang J, Modulatory Mechanisms of the NLRP3 Inflammasomes in Diabetes. *Biomolecules* 9, (2019).
47. Aksentjevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, Stein L, Russo R, Goldsmith D, Dent P, Rosenberg HF, Austin F, Remmers EF, Balow JE Jr., Rosenzweig S, Komarow H, Shoham NG, Wood G, Jones J, Mangra N, Carrero H, Adams BS, Moore TL, Schikler K, Hoffman H, Lovell DJ, Lipnick R, Barron K, O’Shea JJ, Kastner DL, Goldbach-Mansky R, De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. *Arthritis and rheumatism* 46, 3340–3348 (2002). [PubMed: 12483741]
48. Zaki FM, Sridharan R, Pei TS, Ibrahim S, Ping TS, NOMID: the radiographic and MRI features and review of literature. *Journal of radiology case reports* 6, 1–8 (2012).
49. Hill SC, Namde M, Dwyer A, Poznanski A, Canna S, Goldbach-Mansky R, Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA). *Pediatric radiology* 37, 145–152 (2007). [PubMed: 17136361]
50. Feldmann J, Prieur AM, Quartier P, Berquin P, Certain S, Cortis E, Teillac-Hamel D, Fischer A, de Saint Basile G, Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. *American journal of human genetics* 71, 198–203 (2002). [PubMed: 12032915]
51. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD, Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. *Nature genetics* 29, 301–305 (2001). [PubMed: 11687797]
52. Bonar SL, Brydges SD, Mueller JL, McGeough MD, Pena C, Chen D, Grimston SK, Hickman-Brecks CL, Ravindran S, McAlinden A, Novack DV, Kastner DL, Civitelli R, Hoffman HM,

- Mbalaviele G, Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. *PLoS one* 7, e35979 (2012). [PubMed: 22558291]
53. Brydges SD, Broderick L, McGeough MD, Pena CA, Mueller JL, Hoffman HM, Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. *The Journal of clinical investigation* 123, 4695–4705 (2013). [PubMed: 24084736]
 54. Wang C, Xu CX, Alippe Y, Qu C, Xiao J, Schipani E, Civitelli R, Abu-Amer Y, Mbalaviele G, Chronic inflammation triggered by the NLRP3 inflammasome in myeloid cells promotes growth plate dysplasia by mesenchymal cells. *Scientific reports* 7, 4880 (2017). [PubMed: 28687790]
 55. McGeough MD, Wree A, Inzaugarat ME, Haimovich A, Johnson CD, Peña CA, Goldbach-Mansky R, Broderick L, Feldstein AE, Hoffman HM, TNF regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies. *The Journal of clinical investigation* 127, 4488–4497 (2017). [PubMed: 29130929]
 56. Xiao J, Wang C, Yao JC, Alippe Y, Xu C, Kress D, Civitelli R, Abu-Amer Y, Kanneganti TD, Link DC, Mbalaviele G, Gasdermin D mediates the pathogenesis of neonatal-onset multisystem inflammatory disease in mice. *PLoS biology* 16, e3000047 (2018). [PubMed: 30388107]
 57. Kanneganti A, Malireddi RKS, Saavedra PHV, Vande Walle L, Van Gorp H, Kambara H, Tillman H, Vogel P, Luo HR, Xavier RJ, Chi H, Lamkanfi M, GSDMD is critical for autoinflammatory pathology in a mouse model of Familial Mediterranean Fever. *The Journal of experimental medicine* 215, 1519–1529 (2018). [PubMed: 29793924]
 58. Humphries F, Shmuel-Galia L, Ketelut-Carneiro N, Li S, Wang B, Nemmara VV, Wilson R, Jiang Z, Khalighnejad F, Muneeruddin K, Shaffer SA, Dutta R, Ionete C, Pesiridis S, Yang S, Thompson PR, Fitzgerald KA, Succination inactivates gasdermin D and blocks pyroptosis. *Science (New York, N.Y.)* 369, 1633–1637 (2020).
 59. Ter Haar N, Lachmann H, Özen S, Woo P, Uziel Y, Modesto C, Koné-Paut I, Cantarini L, Insalaco A, Neven B, Hofer M, Rigante D, Al-Mayouf S, Touitou I, Gallizzi R, Papadopoulou-Alataki E, Martino S, Kuemmerle-Deschner J, Obici L, Iagaru N, Simon A, Nielsen S, Martini A, Ruperto N, Gattorno M, Frenkel J, Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. *Annals of the rheumatic diseases* 72, 678–685 (2013). [PubMed: 22753383]
 60. Anton J, Calvo I, Fernández-Martin J, Gamir ML, Merino R, Jimenez-Treviño S, Sevilla B, Cabades F, Bou R, Arostegui JI, Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort. *Clinical and experimental rheumatology* 33, S67–71 (2015). [PubMed: 26243511]
 61. Sibley CH, Plass N, Snow J, Wiggs EA, Brewer CC, King KA, Zalewski C, Kim HJ, Bishop R, Hill S, Paul SM, Kicker P, Phillips Z, Dolan JG, Widemann B, Jayaprakash N, Pucino F, Stone DL, Chappelle D, Snyder C, Butman JA, Wesley R, Goldbach-Mansky R, Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. *Arthritis and rheumatism* 64, 2375–2386 (2012). [PubMed: 22294344]
 62. Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, Pinto G, Pagnier A, Bodemer C, Bodaghi B, Tardieu M, Prieur AM, Quartier P, Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. *Arthritis and rheumatism* 62, 258–267 (2010). [PubMed: 20039428]
 63. Rigante D, Leone A, Marrocco R, Laino ME, Stabile A, Long-term response after 6-year treatment with anakinra and onset of focal bone erosion in neonatal-onset multisystem inflammatory disease (NOMID/CINCA). *Rheumatology international* 31, 1661–1664 (2011). [PubMed: 21240490]
 64. Hu JJ, Liu X, Xia S, Zhang Z, Zhang Y, Zhao J, Ruan J, Luo X, Lou X, Bai Y, Wang J, Hollingsworth LR, Magupalli VG, Zhao L, Luo HR, Kim J, Lieberman J, Wu H, FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. *Nature immunology* 21, 736–745 (2020). [PubMed: 32367036]
 65. Deng W, Yang Z, Yue H, Ou Y, Hu W, Sun P, Disulfiram suppresses NLRP3 inflammasome activation to treat peritoneal and gouty inflammation. *Free radical biology & medicine* 152, 8–17 (2020). [PubMed: 32151746]

66. Brydges SD, Mueller JL, McGeough MD, Pena CA, Misaghi A, Gandhi C, Putnam CD, Boyle DL, Firestein GS, Horner AA, Soroosh P, Watford WT, O'Shea JJ, Kastner DL, Hoffman HM, Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. *Immunity* 30, 875–887 (2009). [PubMed: 19501000]
67. Snouwaert JN, Nguyen M, Repenning PW, Dye R, Livingston EW, Kovarova M, Moy SS, Brigman BE, Bateman TA, Ting JP, Koller BH, An NLRP3 Mutation Causes Arthropathy and Osteoporosis in Humanized Mice. *Cell reports* 17, 3077–3088 (2016). [PubMed: 27974218]
68. Garnish SE, Meng Y, Koide A, Sandow JJ, Denbaum E, Jacobsen AV, Yeung W, Samson AL, Horne CR, Fitzgibbon C, Young SN, Smith PPC, Webb AI, Petrie EJ, Hildebrand JM, Kannan N, Czabotar PE, Koide S, Murphy JM, Conformational interconversion of MLKL and disengagement from RIPK3 precede cell death by necroptosis. *Nature communications* 12, 2211 (2021).
69. Sun L, Wang H, Wang Z, He S, Chen S, Liao D, Wang L, Yan J, Liu W, Lei X, Wang X, Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. *Cell* 148, 213–227 (2012). [PubMed: 22265413]
70. Taabazuing CY, Okondo MC, Bachovchin DA, Pyroptosis and Apoptosis Pathways Engage in Bidirectional Crosstalk in Monocytes and Macrophages. *Cell chemical biology* 24, 507–514.e504 (2017). [PubMed: 28392147]
71. Baroja-Mazo A, Martín-Sánchez F, Gomez AI, Martínez CM, Amores-Iniesta J, Compan V, Barberà-Cremades M, Yagüe J, Ruiz-Ortiz E, Antón J, Buján S, Couillin I, Brough D, Arostegui JJ, Pelegrín P, The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. *Nature immunology* 15, 738–748 (2014). [PubMed: 24952504]
72. Franklin BS, Bossaller L, De Nardo D, Ratter JM, Stutz A, Engels G, Brenker C, Nordhoff M, Mirandola SR, Al-Amoudi A, Mangan MS, Zimmer S, Monks BG, Fricke M, Schmidt RE, Espevik T, Jones B, Jarnicki AG, Hansbro PM, Busto P, Marshak-Rothstein A, Hornemann S, Aguzzi A, Kastenmüller W, Latz E, The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation. *Nature immunology* 15, 727–737 (2014). [PubMed: 24952505]
73. Sagoo P, Garcia Z, Breart B, Lemaître F, Michonneau D, Albert ML, Levy Y, Bousso P, In vivo imaging of inflammasome activation reveals a subcapsular macrophage burst response that mobilizes innate and adaptive immunity. *Nature medicine* 22, 64–71 (2016).
74. Mihaly SR, Ninomiya-Tsuji J, Morioka S, TAK1 control of cell death. *Cell death and differentiation* 21, 1667–1676 (2014). [PubMed: 25146924]
75. Legros H, Janin F, Dourmap N, Bonnet JJ, Costentin J, Semi-chronic increase in striatal level of 3,4-dihydroxyphenylacetaldehyde does not result in alteration of nigrostriatal dopaminergic neurones. *Journal of neuroscience research* 75, 429–435 (2004). [PubMed: 14743456]
76. Qu C, Bonar SL, Hickman-Brecks CL, Abu-Amer S, McGeough MD, Peña CA, Broderick L, Yang C, Grimston SK, Kading J, Abu-Amer Y, Novack DV, Hoffman HM, Civitelli R, Mbalaviele G, NLRP3 mediates osteolysis through inflammation-dependent and -independent mechanisms. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 29, 1269–1279 (2015). [PubMed: 25477279]
77. Li S, Wu Y, Yang D, Wu C, Ma C, Liu X, Moynagh PN, Wang B, Hu G, Yang S, Gasdermin D in peripheral myeloid cells drives neuroinflammation in experimental autoimmune encephalomyelitis. *The Journal of experimental medicine* 216, 2562–2581 (2019). [PubMed: 31467036]
78. Lentz EK, Cherla RP, Jaspers V, Weeks BR, Tesh VL, Role of tumor necrosis factor alpha in disease using a mouse model of Shiga toxin-mediated renal damage. *Infection and immunity* 78, 3689–3699 (2010). [PubMed: 20605983]
79. Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP, Ma A, Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. *Science (New York, N.Y.)* 289, 2350–2354 (2000).
80. Biesmans S, Bouwknecht JA, Ver Donck L, Langlois X, Acton PD, De Haes P, Davoodi N, Meert TF, Hellings N, Nuydens R, Peripheral Administration of Tumor Necrosis Factor-Alpha Induces Neuroinflammation and Sickness but Not Depressive-Like Behavior in Mice. *BioMed research international* 2015, 716920 (2015). [PubMed: 26290874]

81. Murphey ED, Traber DL, Protective effect of tumor necrosis factor-alpha against subsequent endotoxemia in mice is mediated, in part, by interleukin-10. *Critical care medicine* 29, 1761–1766 (2001). [PubMed: 11546981]
82. Volchuk A, Ye A, Chi L, Steinberg BE, Goldenberg NM, Indirect regulation of HMGB1 release by gasdermin D. *Nature communications* 11, 4561 (2020).
83. Kayagaki N, Kornfeld OS, Lee BL, Stowe IB, O'Rourke K, Li Q, Sandoval W, Yan D, Kang J, Xu M, Zhang J, Lee WP, McKenzie BS, Ulas G, Payandeh J, Roose-Girma M, Modrusan Z, Reja R, Sagolla M, Webster JD, Cho V, Andrews TD, Morris LX, Miosge LA, Goodnow CC, Bertram EM, Dixit VM, NINJ1 mediates plasma membrane rupture during lytic cell death. *Nature* 591, 131–136 (2021). [PubMed: 33472215]
84. Tschopp J, Schroder K, NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? *Nature reviews. Immunology* 10, 210–215 (2010).
85. Wang C, Hockerman S, Jacobsen EJ, Alippe Y, Selness SR, Hope HR, Hirsch JL, Mnich SJ, Saabye MJ, Hood WF, Bonar SL, Abu-Amer Y, Haimovich A, Hoffman HM, Monahan JB, Mbalaviele G, Selective inhibition of the p38 α MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals. *The Journal of experimental medicine* 215, 1315–1325 (2018). [PubMed: 29549113]
86. Takeshita S, Kaji K, Kudo A, Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research* 15, 1477–1488 (2000).




Figure 1. LPS or TNF- α induced IL-1 β and IL-18 secretion in by *Nlrp3*^{CA/+};*Gsdmd*^{-/-} but not *Gsdmd*^{-/-} mice.

Three-month-old WT, *Gsdmd*^{-/-}, *Nlrp3*^{CA/+}, and *Nlrp3*^{CA/+};*Gsdmd*^{-/-} mice were injected with 15 mg/kg LPS for 6 hours or 0.5 mg/kg TNF- α for 2 hours. PBS-administrated mice served as controls. N=4-6 mice/group. Serum cytokine levels were measured by V-PLEX Plus Proinflammatory Panel 1 Mouse Kit, except for IL-18, which were assessed by ELISA. Data are mean \pm SEM. *P < 0.05; **P < 0.01; ***P < 0.001. One-Way ANOVA. LPS, lipopolysaccharide; IL, interleukin; WT, wild type; ca, constitutive activation; TNF- α , tumor necrosis factor α .




Figure 2. LPS stimulated IL-1β release and GSDME cleavage by *Nlrp3^{CA/+};Gsdmd^{-/-}* BMDMs. BMDMs were expanded *in vitro* in M-CSF-containing media from bone marrow cells isolated from WT, *Nlrp3^{CA/+}*, or *Nlrp3^{CA/+};Gsdmd^{-/-}* mice. BMDMs were primed with 100 ng/ml LPS for 1, 2, 3, or 4 hours and treated with 15 μM nigericin for 20 minutes, 40 minutes, 1, 2, 3, 4 hours. IL-1β (A) and LDH (B) in the conditioned media were measured by ELISA and by the cytotoxicity detection Kit, respectively. (C) The indicated proteins in the whole cell lysates were analyzed by immunoblotting. Data are mean ± SEM from experimental triplicates and are representative of at least three independent experiments. **P < 0.01; ***P < 0.001; ##P < 0.01; ###P < 0.001. **,*** *Nlrp3^{CA/+}* or *Nlrp3^{CA/+};Gsdmd^{-/-}* compared to WT; ##, ### *Nlrp3^{CA/+};Gsdmd^{-/-}* compared to *Nlrp3^{CA/+}*. One-Way ANOVA. BMDMs, bone marrow-derived macrophages; cCasp, cleaved caspase; cGSDM, cleaved gasdermin; h, hour; IL-1β, interleukin-1β; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; min, minute; M-CSF, macrophage colony-stimulating factor; WT, wild type; CA, constitutive activation.




Figure 3. GSDME was involved in IL-1 β and IL-18 secretion induced by LPS or TNF- α in *Nlrp3*^{CA/+};*Gsdmd*^{-/-} mice.

Three-month-old WT, *Gsdme*^{-/-}, *Gsdme*^{-/-} and *Gsdmd*^{-/-};*Gsdme*^{-/-} mice (**A**) or WT, *Nlrp3*^{CA/+}, *Nlrp3*^{CA/+};*Gsdmd*^{-/-} and *Nlrp3*^{CA/+};*Gsdmd*^{-/-};*Gsdme*^{-/-} mice (**B**) were injected with 15 mg/kg LPS for 6 hours or 0.5 mg/kg TNF- α for 2 hours. PBS-administrated mice served as controls. N=3-5 mice/group. Serum cytokine levels were measured by V-PLEX Plus Proinflammatory Panel 1 Mouse Kit, except for IL-18, which were assessed by ELISA. Data are mean \pm SEM. ***P < 0.001. One-Way ANOVA. LPS, lipopolysaccharide; IL, interleukin; WT, wild type; CA, constitutive activation; TNF- α , tumor necrosis factor α .




Figure 4. GSDME was cleaved in *Gsdmd*^{-/-} BMDMs and involved in IL-1 β and LDH release. BMDMs from bone marrow isolated from WT, *Gsdmd*^{-/-}, *Gsdme*^{-/-} or *Gsdmd*^{-/-};*Gsdme*^{-/-} mice were expanded *in vitro* in M-CSF-containing media. BMDMs were primed with 100 ng/ml LPS for 3 hours and treated with 15 μ M nigericin for 20 minutes, 40 minutes, 1, 2, 3, 4 hours. (A) The indicated proteins in the whole cell lysates were analyzed by immunoblotting. IL-1 β (B) and LDH (C) in the conditioned media were measured by ELISA and by the cytotoxicity detection Kit, respectively. Data are mean \pm SD from experimental triplicates and are representative of at least three independent experiments. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$. *, **, *** compared to WT. One-Way ANOVA. BMDMs, bone marrow-derived macrophages; cCasp, cleaved caspase; cGSDM, cleaved gasdermin; h, hour; IL-1 β , interleukin-1 β ; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; min, minute; nig, nigericin; M-CSF, macrophage colony-stimulating factor; WT, wild type.




Figure 5. GSDME was involved in IL-1 β and LDH release by *Nlrp3^{CAI+};Gsdmd^{-/-}* BMDMs. BMDMs were expanded *in vitro* in M-CSF-containing media from bone marrow cells isolated from WT, *Nlrp3^{CAI+}*, *Nlrp3^{CAI+};Gsdmd^{-/-}*, *Nlrp3^{CAI+};Gsdmd^{-/-};Gsdme^{-/-}* mice. BMDMs were treated with 100 ng/ml LPS for 3, 6, 9, 12, 18 or 24 hours. IL-1 β (A) and LDH (B) in the conditioned media were measured by ELISA and by the cytotoxicity detection Kit, respectively. Data are mean \pm SEM from experimental triplicates and are representative of at least three independent experiments. **P < 0.01; ***P < 0.001; ###P < 0.01; ####P < 0.001. ****Nlrp3^{CAI+};Gsdmd^{-/-}* or *Nlrp3^{CAI+};Gsdmd^{-/-};Gsdme^{-/-}* compared to *Nlrp3^{CAI+}*, ####*Nlrp3^{CAI+};Gsdmd^{-/-};Gsdme^{-/-}* compared to *Nlrp3^{CAI+};Gsdmd^{-/-}*. One-Way ANOVA. BMDMs, bone marrow-derived macrophages; h, hour; IL-1 β , interleukin-1 β ; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; M-CSF, macrophage colony-stimulating factor; WT, wild type; CA, constitutive activation.




Figure 6. CuET inhibited GSDMD, GSDME, and IL-1 β maturation and LDH release. BMDMs were expanded *in vitro* in M-CSF-containing media from bone marrow cells isolated from WT, *Gsdmd*^{-/-}, *Gsdme*^{-/-}, or *Gsdmd*^{-/-};*Gsdme*^{-/-} mice. BMDMs were primed with 100 ng/ml LPS for 3 hours and treated with vehicle or CuET for 1 hour before adding 15 μ M nigericin for 3 hours. (A) The indicated proteins in the whole cell lysates were analyzed by immunoblotting. IL-1 β (B) and LDH (C) in the conditioned media were measured by ELISA and by the cytotoxicity detection Kit, respectively. Data are mean \pm SD from experimental triplicates and are representative of at least three independent experiments. **P < 0.01; ***P < 0.001. Two-Way ANOVA. BMDMs, bone marrow-derived macrophages; cCasp, cleaved caspase; cGSDM, cleaved gasdermin; h, hour; IL-1 β , interleukin-1 β ; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; min, minute; nig, nigericin; M-CSF, macrophage colony-stimulating factor; WT, wild type.




Figure 7. CuET inhibited NLRP3 inflammasome-dependent but not -independent responses. BMDMs were expanded *in vitro* M-CSF-containing media from bone marrow cells isolated from WT or *Gsdmd*^{-/-} mice. (A) WT BMDMs were pretreated with vehicle or CuET for 1 hour, and were stimulated with vehicle or 10 μ M Raptinal for 1 hour. (B) WT and *Gsdmd*^{-/-} BMDMs were pretreated with vehicle or CuET for 1 hour, and were stimulated with 100 ng/ml TNF- α and 1 μ M 5Z-7-oxozeaenol (TAK1 inhibitor) for 4 hours. The indicated proteins in the whole cell lysates were analyzed by immunoblotting (A and B). (C) WT BMDMs from *Asc-citrine* mice were primed with 100 ng/ml LPS for 3 hours and treated with vehicle or 1 μ M CuET for 15 minutes, then with 15 μ M nigericin for additional 30 minutes. ASC specks were visualized under fluorescence microscopy and quantified using imageJ. Data are mean \pm SEM from experimental triplicates and are representative of at least three independent experiments. ***P < 0.001. One-Way ANOVA. BMDMs, bone marrow-derived macrophages; cCasp, cleaved caspase; CuET, bis(diethyldithiocarbamate)-copper; cGSDM, cleaved gasdermin; h, hour; LPS, lipopolysaccharide; nig, nigericin; M-CSF, macrophage colony-stimulating factor; WT, wild type.




Figure 8. CuET prevented inflammasomopathy in the inducible NLRP3^{CA/+} (iNLRP3^{CA/+}) model.

Three-month-old mice were injected with tamoxifen once every other day, 3 times a week for 2 weeks. Injections with vehicle or 1 mg/kg body weight CuET started 2 days before the tamoxifen regimen, and were carried out once every other day, 3 times a week for 6 weeks. All injections were given intraperitoneally. N=6-11 mice/group. (A) Body weight change, spleen weight, WBC; and neutrophils. Data are means \pm SEM. Two-Way ANOVA. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$. (B) Representative H&E staining of liver and spleen sections. WBC, white blood cell; WT, wild-type; CA, constitutive activation; CuET, bis(diethylthiocarbamate)-copper; iNLRP3^{CA/+}, inducible NLRP3^{CA/+}.